november AG
november AG english
november AG speeds up preparation for market introduction
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG speeds up preparations for market introduction of its biotech-based
product security system timed for late 2002
Erlangen, May 28, 2002. In the first quarter of 2002, the Erlangen based biotech
company november AG has been speeding up its activities for a broad market
introduction of its “identif Technologies”. These novel biotechnological
technologies allow forgery-proof labeling of products as well as supply chain
surveillance. Despite 35 percent higher expenses for research and development
amounting to EUR 1.6 million (previous year: EUR 1.2 million) and a rise in
employees (91 compared to 83 in the first quarter of 2001), the operating loss
of EUR 2.14 million is only slightly above the result of the previous year (EUR
2.04 million). The consolidated net loss was reduced from EUR 1.43 million to
EUR 1.15 million, which is mainly due to taxation effects. Revenues in the
reporting period amounted to EUR 0.81 million (previous year: EUR 1.00 million).
On an adjusted basis, that is without the la fontaine International companies
which were deconsolidated effective of end of May 2001, the consolidated
revenues rose by 18 percent in comparison to previous year’s period. On March
31, 2002, the balance sheet total amounted to EUR 33.5 million. With equity of
EUR 30.9 million, the equity ratio amounts to 92 percent. The undiluted earnings
per share (EPS and DVFA/SG) are EUR -0.17 (previous year: EUR -0.22). For 2002,
the executive board estimates a net loss per share, including income from
deferred tax, in the range of 75 to 90 Euro cent (2001: EUR -1,07).
During the first quarter of 2002, november AG was able to gain further
technology partners as well as marketing partners which add to the existing
cooperation with Siemens Automation and Drives: Infineon Technologies AG,
Bundesdruckerei GmbH, and the US-American KIG, Ltd., an internationally active
marketing company for sports and entertainment. Together with these partners,
november AG plans to introduce identif Technologies to the market as early as in
the end of this year. Also on plan are the other projects of november AG, like
the automated mini-lab) within the business unit of Molecular Diagnosis
(partner: Siemens Medical Solutions or the novel immunotherapeutic cancer
therapy approach within Molecular Therapy.
november AG
Christian Fenner
Tel. +49 9131-75088868
E-mail: fenner@november.de
end of ad-hoc-announcement (c)DGAP 28.05.2002
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, München, Hannover und Stuttgart
280800 Mai 02
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden